Author:
Dang Xiuyong,Ye Shiguang,Zhou Lili,Lu Yan,Li Ping,Liang Aibin,Qian Wenbin
Subject
Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy
Reference27 articles.
1. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium;Nastoupil;J Clin Oncol,2020
2. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies;Sermer;Blood Adv,2020
3. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma;Neelapu;Blood,2020
4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial;Locke;The Lancet Oncology,2019
5. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study;Schuster;Lancet Oncol,2021